-
Crisaborole
API Nomen Indicium Innovator Exitus patentibus Date (US) Crisaborole Atopic Dermatitis et Eczema Pfizer -
Etelcacetide
API Nomen Indicium Innovator Exitus patentibus Date (US) Etelcacetide Secundarium hyperparathyroidism (HPT) Amgen -
Abemaciclib
API Nomen Indicium Innovator Exitus patentibus Date (US) Abemaciclib Cancer pectus, cancer prostatae curatio Eli Lily Dec.15,2029 -
Deucracitinib
API Nomen Indicium Innovator Exitus patentibus Date (US) Deucracitinib Anti plaque psoriasis Bristol-Myers Squibb Company Nov.07,2033 -
Apremilast
API Nomen Indicium Innovator Exitus patentibus Date (US) Apremilast psoriatic arthritis Celgene -
Remdesivir
API Nomen Indicium Innovator Exitus patentibus Date (US) Remdesivir Antiviruls(Ebola, Covid-19) Galaad -
Paxlovid
API Nomen Indicium Innovator Exitus patentibus Date (US) Paxlovid Covid 19 Pfizer -
Pomalidomide
API Nomen Indicium Innovator Exitus patentibus Date (US) Pomalidomide Oncology medicamento Celgene -
Nirmatrelvir
API Nomen Indicium Innovator Exitus patentibus Date (US) Nirmatrelvir 3C-Sicut Protease (3CLPRO) Inhibitor And SARS-Cov-2 Mpro Inhibitor -
Eltrombopag
API Nomen Indicium Innovator Exitus patentibus Date (US) Eltrombopag ITP & Aplastic anemia Novartis & GSK Kalendas lunii. 20, 2023 -
Ruxolitinib
API Nomen Indicium Innovator Exitus patentibus Date (US) Ruxolitinib Myelofibrosis Novartis 6, 2024 -
Crisaborole
API Nomen Indicium Innovator Exitus patentibus Date (US) Crisaborole Atopic DERMATITIS et Eczema Pfizer 11 Iun